A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the effect of induction MEPFL chemotherapy followed by concurrent chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with advanced NPC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients

NCT02604472

Malignant Neoplasm of Other Specified Site of Nasopharynx

COMPLETED

A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients

NCT00201344

Nasopharyngeal Carcinoma

TERMINATED PHASE3

Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

NCT04414566

Nasopharyngeal Carcinoma

UNKNOWN PHASE3

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

NCT00686322

Non-small-cell Lung Cancer

COMPLETED PHASE4

GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

NCT03604965

Locally Advanced Nasopharyngeal Carcinoma

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale of induction chemotherapy:

Distant metastasis is the major cause of treatment failure and deaths in patients with loco-regionally advanced NPC.

Concurrent chemoradiotherapy may prolong survivals for patients with advanced NPC, but it is still flawed by high incidence of distant metastasis.

Induction chemotherapy with MEPFL has been shown to reduce the incidence of distant metastasis in a Phase II study.

Induction chemotherapy plus concurrent chemoradiotherapy may improve the survival of patients with advanced NPC.

Objectives:

Investigate the effect of induction MEPFL chemotherapy followed by concurrent chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with advanced NPC.

Study design:

This is a randomized, multi-center Phase III study. Patients will be randomized to CCRT with or without the MEPFL induction chemotherapy.

Type and number of patients:

Patients with stage IVA (T4) and/or IVB (N3) but without distant metastasis will be enrolled. A total of up to 480 patients will be randomized to detect an improvement of median overall survival from 5.8 to 8.7 years, with an a=0.05 and power of 0.8 using a two-sided logrank test with one interim analysis.

Treatment schedule:

Induction chemotherapy and CCRT:

Arm A: Weekly cisplatin concurrently with radiotherapy Arm B: Induction MEPFL three cycles followed with weekly cisplatin concurrently with radiotherapy.

Study endpoints:

The primary endpoint is the disease-free survival that will be calculated as the duration between the date of randomization and the date of recurrence of NPC at any site including persistent disease after +induction chemotherapy/CCRT, or death from any cause (failed), or the date of withdrawal (last contact date, censored), or the scheduled data analysis date (censored).( revised 8/27/2004)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasopharyngeal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A arm

CCRT

Group Type ACTIVE_COMPARATOR

CCRT

Intervention Type RADIATION

Radiation with weekly Cisplatin

B arm

Induction/CCRT

Group Type EXPERIMENTAL

CCRT

Intervention Type RADIATION

Radiation with weekly Cisplatin

Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin

Intervention Type DRUG

Induction C/T + CCRT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CCRT

Radiation with weekly Cisplatin

Intervention Type RADIATION

Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin

Induction C/T + CCRT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proved nasopharyngeal carcinoma.
* T4NxM0 or TxN3M0 disease by UICC/AJCC 1997 staging system. (30)
* Eastern Cooperative Oncology Group performance status \< 2.
* A leukocyte count ≥3750/mL, Hb ≥ 10 g/dL, and a platelet count ≥100,000/mL.
* A serum bilirubin level \< 1.5 mg/dL, serum creatinine level \< 1.6 mg/dL or creatinine clearance \> 60 mL/min.
* Age less than 70 years old
* An informed consent signed.

Exclusion Criteria

* Evidence of metastatic disease.
* Presence of another malignancy other than treated squamous/basal cell carcinoma of the skin.
* Presence of uncontrolled hypertension, poorly controlled heart failure.
* Presence of active infection.
* Patients who have been or are being treated with chemotherapy, radiotherapy, immunotherapy, or other experimental therapies.
* Women who test positive for pregnancy.

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No